Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.

  title={Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.},
  author={Raymond Taetle and B Dos Santos and Yoshiyuki Ohsugi and Yasuo Gotenba-shi Koishihara and Y. Yamada and Hans A. Messner and W Dalton},
  journal={Journal of the National Cancer Institute},
  volume={86 6},
BACKGROUND Although passive serotherapy for cancer with monoclonal antibodies is an attractive concept, it has unfortunately had limited efficacy in clinical trials. An alternative approach to passive serotherapy is targeting cell surface growth factor receptors with monoclonal antibodies. With some limitations, anti-growth factor receptor antibodies can limit cell growth by blocking stimulatory or trophic growth factor receptors and by marshaling in vivo antitumor immune responses. PURPOSE… Expand
Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Flow cytometry rapidly detects apoptosis induced by biological agents and may be useful for in vitro screening of novel biological therapies. Expand
Monoclonal and bispecific antibodies as novel therapeutics
This review discusses antibody-based therapeutic products used in clinical practice, discusses the clinical usage of bispecific antibodies and antibodies “armed” with cytotoxic agents or enzymes, and deliberates upon potential problems associated with cancer immunotherapy. Expand
Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
  • D. Brooks, C. Taylor, +5 authors R. Taetle
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1995
Results of a Phase Ia trial of IgA monoclonal anti-Tf receptor antibody 42/6 represent the first clinical trial of an IgA mouse mAb, and one of only a few trials in which an antibody reacting with a broad range of normal tissues has been administered. Expand
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
How the antibody-based therapies will evolve, including the use of antibodies in combinations, their main characteristics, advantages, and how they could contribute to significantly increase the chances of success in cancer therapy are described. Expand
Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
Human IgG monoclonal antibodies to human TFR1 are developed using a phage display method to block the incorporation of the transferrin (TF)-iron complex into ATLL cells for inhibiting cell growth and JST-TFR09, described here may become a promising therapeutic antibody for the treatment of ATLL. Expand
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Although TfR1 has been used extensively as a target for antibody-mediated cancer therapy over the years, interest continues to increase for both targeting the receptor for delivery purposes and for its use as direct anti-cancer agents. Expand
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.
Improvements in the basic physiology of the transferrin receptor including structure, function, and expression are summarized and the efficacy of targeting the TfR using cytotoxic antibodies that inhibit cell growth and/or induce apoptosis in targeted malignant cells is discussed. Expand
Dexamethasone plus retinoids decrease IL‐6/IL‐6 receptor and induce apoptosis in myeloma cells
Combinations of RA + DEX were not only more effective in inhibiting myeloma cells growth by the dual mechanisms of decreasing proliferative fraction and increasing apoptotic fraction, but were also less able to be overcome by IL‐6. Expand
Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia
HLA class I and II antigens were detected using HLA typing on all cell lines warranting their use as suitable targets for HLA‐restricted cytotoxic T cells. Expand
Fas/Fas ligand (FasL)‐deregulated apoptosis and IL‐6 insensitivity in highly malignant myeloma cells
Evidence is provided that concurrence of IL‐6 insensitivity and deregulation of apoptosis in myeloma cells reflects a high malignancy grade, and it is suggested that the secretion of Fas splicing variants in Fas+ plasma cells, as well as the over‐production of FasL in Fas− myelomas, are differential mechanisms by which myel cancer cells escape host immune surveillance. Expand